One-glance verdict
Not enough data
Fair value unavailable
Not enough cash-flow history to value this one with our method.
Fundamentals snapshot
PROCEPT BioRobotics Corporation
PRCT · NGM · Healthcare · Medical Devices
Current price
$20.27
52-week range
$16.66 - $38.11
Market cap
$1.15B
Balance sheet
Healthy
-28.96x Concerning
Net cash $150.41M. Interest coverage shows how many times profit covers the interest bill.
What stands out
1 Reward
1 Risk
1 rewards · 1 risks
- Reward Revenue grew 14.4% last year.
- Risk Return on equity was -30.2% last year — the company lost money on shareholders' equity.
What this company does
PROCEPT BioRobotics Corporation
PROCEPT BioRobotics Corporation makes robotic systems that help surgeons perform less invasive procedures to treat prostate issues, primarily selling these high-tech machines and the supplies used with them. The company's success relies on selling these expensive systems and then generating ongoing income from the disposable components needed for each surgery, which is similar to how a printer company makes money from ink cartridges. This combination of upfront sales and recurring revenue (money that comes in regularly and predictably) is important because it suggests a stable business model for future growth.
How the company got here
PROCEPT BioRobotics was founded in 2007 with a vision to revolutionize minimally invasive surgery, particularly in urology. The company focused on developing robotic systems that could offer greater precision and better patient outcomes. A key turning point was the development and FDA approval of their AquaBeam Robotic System, which paved the way for their innovative Aquablation therapy. This allowed them to move from concept to a commercialized product, establishing their presence in the medical device market.
What it actually does
PROCEPT BioRobotics creates advanced robotic systems designed for surgical procedures. Think of it like a highly sophisticated, image-guided robot that surgeons use to perform operations with more accuracy. Their main focus is on urology, which deals with the urinary tract and male reproductive organs. The goal is to make surgeries less invasive, meaning smaller incisions, quicker recovery times, and potentially fewer complications for patients.
Urology Solutions
This is PROCEPT BioRobotics' primary business, centered around treating conditions like benign prostatic hyperplasia (BPH), a common issue for older men where the prostate gland enlarges. They offer the AquaBeam Robotic System and the HYDROS Robotic System, which together enable Aquablation therapy. This therapy uses a robotic wand and water jet to precisely remove prostate tissue causing urinary problems, all while guided by real-time imaging. Patients with lower urinary tract symptoms due to BPH are the direct beneficiaries, and hospitals and urologists are the customers who purchase or use these systems.
What management is betting on now
Management is focused on expanding the adoption of their Aquablation therapy and robotic systems. This involves increasing the number of hospitals and surgeons using their technology, both in the United States and internationally. They are also likely investing in further research and development to enhance their existing products and potentially explore new applications for their robotic surgery platform. The strategy hinges on demonstrating the clinical and economic benefits of their approach to healthcare providers, ultimately driving revenue growth.
Price history
How the share price has moved
—
Loading price history…
Earnings history
Last 8 quarters — what happened
Click any quarter to read the call summary and what the numbers say.
FY2024 Q4
$-33.56M
FY2025 Q1
$-18.82M
FY2025 Q2
$-17.84M
FY2025 Q3
$-9.50M
FY2025 Q4
$-12.18M
FY2026 Q1
$-41.04M
FY2026 Q2
$-22.20M
FY2026 Q3
$-9.65M
Revenue
$98.29M
Net income
$-26.52M
Diluted EPS
-0.46
Operating cash flow
$-8.98M
Free cash flow
$-9.65M
Fetching…
Sources
Revenue
$94.50M
Net income
$-26.86M
Diluted EPS
-0.47
Operating cash flow
$-19.25M
Free cash flow
$-22.20M
Fetching…
Sources
Revenue
$83.13M
Net income
$-31.64M
Diluted EPS
-0.56
Operating cash flow
$-38.13M
Free cash flow
$-41.04M
Fetching…
Sources
Revenue
$76.38M
Net income
$-29.85M
Diluted EPS
-0.54
Operating cash flow
$-10.33M
Free cash flow
$-12.18M
Fetching…
Sources
Revenue
$83.33M
Net income
$-21.41M
Diluted EPS
-0.38
Operating cash flow
$-6.63M
Free cash flow
$-9.50M
Fetching…
Sources
Revenue
$79.18M
Net income
$-19.58M
Diluted EPS
-0.35
Operating cash flow
$-15.04M
Free cash flow
$-17.84M
Fetching…
Sources
Revenue
$69.16M
Net income
$-24.74M
Diluted EPS
-0.45
Operating cash flow
$-16.98M
Free cash flow
$-18.82M
Fetching…
Sources
Revenue
$68.24M
Net income
$-18.86M
Diluted EPS
-0.34
Operating cash flow
$-32.39M
Free cash flow
$-33.56M
Fetching…
Sources
Is it cheap or expensive?
Fair value — vs current price $20.27
We couldn't calculate a fair value right now.
Is it drowning in debt?
Healthy
Net cash $150.4M - more cash than debt. Interest coverage -29.0x.
Net debt
$-150.41M
Interest coverage
-28.96x
PROCEPT BioRobotics Corporation's profit covers its interest bill about 0.0 times over. which is weaker than most peers shown here and 1 peers sit below 1x, which is the danger zone where profit does not fully cover the interest bill.
Healthy
Worse cushion
Baseline
Better cushion
PRCT
BASELINE
PROCEPT BioRobotics Corporation
Total debt $77.50M Interest coverage -28.96x This is the baseline the peer rows are being compared against.
Total debt $28.61M Interest coverage 371.93x This peer still has a real interest-payment cushion, while PRCT does not.
Total debt $727.35M Interest coverage -4.03x Neither company has much profit cushion over interest right now.
Total debt $209.39M Interest coverage 144.35x This peer still has a real interest-payment cushion, while PRCT does not.
What you should know
The case for and against PRCT
1 Reward
1 Risk
Rewards
-
Revenue grew 14.4% last year.
Risks
-
Return on equity was -30.2% last year — the company lost money on shareholders' equity.
The numbers
All the key metrics, grouped by purpose
Tap any ? icon to learn what it means.
Valuation
How expensive the stock looks
P/E (TTM)
—
Forward P/E
-17.30x
P/B
3.12x
P/S
3.42x
EV/EBITDA
-9.90x
PEG ratio
—
Profitability
How much profit each dollar creates
Gross margin
63.4%
Operating margin
-32.1%
Net margin
-32.5%
ROE
-30.2%
ROA
-14.8%
Health
Liquidity and balance-sheet strength
Debt / equity
0.23x
Current ratio
6.55x
Quick ratio
5.23x
Total debt
$77.50M
Total cash
$227.91M
Growth
How the business has been compounding
Revenue TTM
$352.30M
Revenue 5Y CAGR
72.9%
EPS TTM
-1.94
EPS 5Y CAGR
—
Cash flow
How much cash the business throws off
Operating CF TTM
$-76.69M
Free CF TTM
$-58.34M
FCF margin
-16.6%
Dividend
Shareholder payout
Yield
0.0%
Payout ratio
0.0%
Last ex-div date
—